SKYE Skye Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1516551 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.5%
TTM EPS YoY126.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-220.3%
ROA-162.4%
ROIC (approx.)-557.6%
Asset turnover—
Leverage & solvency
Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.36x
Interest coverage-4,388.42x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.32M | $3.94M | $7.94M | $11.47M | $9.36M | $14.34M | $7.20M | $7.79M |
| SG&A expense | $3.66M | $3.87M | $4.74M | $3.43M | $3.91M | $3.91M | $4.56M | $4.55M |
| Operating income | $26,317 | -$11.06M | -$12.67M | -$14.90M | -$13.26M | -$18.24M | -$11.76M | -$10.67M |
| Interest expense | $3,299 | $3,299 | $2,199 | $0 | $0 | $0 | $1,452 | -$46,914 |
| Pretax income | $69,126 | -$10.78M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | -$11.10M | -$9.75M |
| Income tax | $0 | $3,400 | $0 | $0 | $0 | $3,400 | $2,000 | $0 |
| Net income | $69,126 | -$10.79M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | -$11.10M | -$9.75M |
| EBITDA | $57,642 | -$10.90M | -$12.50M | -$14.72M | -$13.09M | -$18.06M | -$11.58M | -$10.49M |
| EPS (basic) | 0.01 | -0.27 | -0.32 | — | -2.57 | -0.44 | -0.28 | — |
| EPS (diluted) | 0.01 | -0.27 | -0.32 | — | -2.57 | -0.44 | -0.28 | — |
| Weighted avg. shares (diluted) | 4.99M | 39.69M | 39.68M | — | 4.96M | 39.66M | 39.65M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.82M | $8.07M | $8.15M | $5.88M | $18.44M | $23.84M | $46.42M | $68.42M |
| Short-term investments | $0 | $2.00M | $8.96M | $19.85M | $16.87M | $24.75M | $12.80M | $0 |
| Current assets | $5.04M | $10.96M | $18.57M | $27.09M | $39.92M | $50.58M | $63.03M | $70.83M |
| PP&E, net | $20,430 | $32,939 | $756,077 | $898,930 | $1.03M | $1.17M | $1.30M | $1.43M |
| Total assets | $5.07M | $11.03M | $19.42M | $28.31M | $41.32M | $52.16M | $64.79M | $72.76M |
| Current liabilities | $3.71M | $11.53M | $10.40M | $8.21M | $8.37M | $8.31M | $5.32M | $4.34M |
| Total liabilities | $3.71M | $11.53M | $10.40M | $8.29M | $8.49M | $8.48M | $5.54M | $4.61M |
| Shareholders' equity | $1.36M | -$497,307 | $9.01M | $20.02M | $32.84M | $43.68M | $59.25M | $68.15M |
| Shares outstanding | 4.42M | 35.14M | 35.13M | 4.17M | 30.99M | 30.99M | 30.97M | 30.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.13M | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | -$9.19M | -$8.17M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $6,312 | $50,024 |
| Free cash flow | -$5.13M | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | -$9.19M | -$8.22M |
| Investing cash flow | $2.00M | $7.14M | $10.90M | -$2.80M | $7.97M | -$11.86M | -$12.81M | $90,410 |
| Financing cash flow | -$116,712 | -$101,014 | -$71,525 | $11,413 | $0 | $18,158 | $0 | $5,618 |
| Depreciation & amortization | $31,325 | $157,598 | $172,886 | $180,009 | $178,898 | $187,066 | $177,379 | $175,293 |
| Stock-based compensation | $1.80M | $1.27M | $1.50M | $1.62M | $1.91M | $2.03M | $2.20M | $2.09M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.